| Methods |
Single‐centre RCT
2 arms
Quality score: B |
| Participants |
n = 121
Metastatic disease: 90%
ECOG 2‐3: 12% |
| Interventions |
FP: 5‐FU 1000 mg/m² over 6 hours d 1‐5; cisplatin 60 mg/m² d 1, repeated at d 29 versus
ECF: epirubicine 50 mg/m² d 1; cisplatin 60 mg/m² d 1, 5‐FU: 1000 mg/m² d 1‐5, repeated at d 29 |
| Outcomes |
Median survival
1‐ and 2‐year survival rates
Response rates
Toxicity |
| Notes |
Study currently published as abstract only. Final results were provided by the first author. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Abstract / supplement only |
| Allocation concealment (selection bias) |
Unclear risk |
Abstract / supplement only |
| Incomplete outcome data (attrition bias)
efficacy |
Unclear risk |
Abstract / supplement only |
| Incomplete outcome data (attrition bias)
safety |
Unclear risk |
Abstract / supplement only |
| Selective reporting (reporting bias) |
Low risk |
Report includes all expected outcomes |
| Other bias |
Unclear risk |
Abstract / supplement only |
| Blinded review of CT/MRI‐scans? |
High risk |
Per first author |
